All In Biotech

NDA 021862 · Harrow Eye

Nevanac

Nepafenac · Ophthalmic · Nonsteroidal Anti-inflammatory Drug

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Aug 19, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

12 Phase 3, 1 recruiting

FAERS reports

893

546 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2024.

NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery. ( 1 )

Mechanism: After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 19, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
1 products under this application
  • NEVANAC · NEPAFENAC 0.1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nepafenac" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective124
  • treatment failure107
  • off label use54
  • vision blurred52
  • cataract46
  • visual acuity reduced44
  • visual impairment40
  • eye pain35
  • macular oedema35
  • nausea33
  • fatigue32
  • headache30

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20054
200664
200711
200814
200913
201017
201118
201247
201328
201439
201551
2016121
201746
201851
201939
2020141
202136
202238
202344
202432
202530
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nevanac (Nepafenac)

2024 spending

$1.7M

Beneficiaries

1,397

3,362 claims

Per beneficiary

$1,235

$109.81 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,544,916
2024$1,725,616

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 83 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.